Celgene tweaks trial of myeloma CAR-T bb2121, raising dose

Celgene says it has raised the top dose and expanded its trial of its anti-BCMA CAR-T candidate for myeloma licensed from Bluebird Bio, but the company still thinks it’s on course for approval i…
Read the full story: FierceBiotech: Biotech